Citius Oncology Inc (CTOR)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
$0.52-9.85%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
Research Workspace
Put CTOR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Increase revenue through LYMPHIR market acceptance: Comparison needs review.
View ThesisThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 72% in its worst 12-month stretch.
View RiskCTOR’s case rests on LYMPHIR gaining market acceptance and growing revenue. Recent results show weak financial performance, with no revenue trend provided. LYMPHIR wholesaler sales rose 120%, supporting acceptance. Sell-through and lasting demand remain unconfirmed. The desk provides no current valuation multiple or peer comparison. Its expectations read is also unavailable. Our model puts the next-quarter miss probability at 35%. The LYMPHIR comparison needs review, so this is not a confirmed break. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. CTOR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering CTOR (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CTOR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CTOR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put CTOR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase revenue through LYMPHIR market acceptance
A reported 120% increase in wholesaler sales supports LYMPHIR market acceptance, though sell-through and durability remain unconfirmed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Increase revenue through LYMPHIR market acceptance
Q3 revenue miss impacts growth expectations for LYMPHIR.
Advances: Increase revenue through LYMPHIR market acceptance
Expansion supports revenue growth through market acceptance.
